Keyphrases
Blood-brain Barrier
30%
Brain Metastases
100%
Cancer Patients
30%
Central Effects
10%
Central Nervous System
10%
Central Nervous System Effects
100%
Change from Baseline
10%
Current Pain
10%
First Dose
20%
First Treatment
10%
Gastrointestinal
10%
In Cancer
10%
Methylnaltrexone
100%
No Significant Difference
10%
Opioid Antagonist
10%
Opioid Withdrawal
20%
Opioid-induced Constipation
30%
Opioids
10%
Pain Score
20%
Penetrance
10%
Placebo
50%
Randomized Double-blind Study
100%
Randomized Placebo-controlled Trial
10%
Structural Properties
10%
Treatment Group
10%
Treatment-related Adverse Events
20%
Medicine and Dentistry
17 Methylnaltrexone
100%
Adverse Event
18%
Blood Brain Barrier
27%
Brain Metastasis
100%
Carbetimer
9%
Central Nervous System
100%
Constipation
27%
Laxative
18%
Malignant Neoplasm
18%
Opiate
54%
Opiate Antagonist
9%
Penetrance
9%
Placebo
54%
Post-Hoc Analysis
100%
Withdrawal Syndrome
9%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
18%
Blood-Brain Barrier
27%
Brain Metastasis
100%
Carbetimer
9%
Constipation
27%
Laxative
18%
Malignant Neoplasm
27%
Methylnaltrexone
100%
Narcotic Antagonist
9%
Opiate
54%
Placebo
54%
Withdrawal Syndrome
9%
Neuroscience
Blood Brain Barrier
30%
Central Nervous System
100%
Methylnaltrexone
100%
Narcotic Antagonist
10%
Opiate
60%
Placebo
60%
Withdrawal Syndrome
10%